Safety of PSMA radioligand therapy in mCRPC patients with preexisting moderate to severe thrombocytopenia

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
Extent
1 Online-Ressource.
Language
Englisch

Bibliographic citation
Safety of PSMA radioligand therapy in mCRPC patients with preexisting moderate to severe thrombocytopenia ; day:3 ; month:12 ; year:2024 ; pages:1-7
European journal of nuclear medicine and molecular imaging ; (3.12.2024), 1-7

Creator
Bastian, Moritz B.
Sieben, Maike
Blickle, Arne
Burgard, Caroline
Speicher, Tilman
Bartholomä, Mark
Schaefer-Schuler, Andrea
Maus, Stephan
Ezziddin, Samer
Rosar, Florian
Contributor
SpringerLink (Online service)

DOI
10.1007/s00259-024-07006-z
URN
urn:nbn:de:101:1-2502172228431.963939409606
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:31 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Bastian, Moritz B.
  • Sieben, Maike
  • Blickle, Arne
  • Burgard, Caroline
  • Speicher, Tilman
  • Bartholomä, Mark
  • Schaefer-Schuler, Andrea
  • Maus, Stephan
  • Ezziddin, Samer
  • Rosar, Florian
  • SpringerLink (Online service)

Other Objects (12)

Long-term nephrotoxicity of 177Lu-PSMA radioligand therapy

Long-term nephrotoxicity of 177Lu-PSMA radioligand therapy

Thromboembolism after COVID-19 vaccine in patients with preexisting thrombocytopenia

Thromboembolism after COVID-19 vaccine in patients with preexisting thrombocytopenia

Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)

Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)

Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)

Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)

Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with 131I-MIP-1095

Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with 131I-MIP-1095

177Lu-rhPSMA-10.1 induces tumor response in a patient with mCRPC after PSMA-directed radioligand therapy with 177Lu-PSMA-I AND T

177Lu-rhPSMA-10.1 induces tumor response in a patient with mCRPC after PSMA-directed radioligand therapy with 177Lu-PSMA-I AND T

Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer

Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer

Combination therapies to enhance the efficacy of PSMA-targeted radioligand therapy in prostate cancer

Combination therapies to enhance the efficacy of PSMA-targeted radioligand therapy in prostate cancer

Bone marrow impairment during early [177Lu]PSMA-617 radioligand therapy: Haematotoxicity or tumour progression?

Bone marrow impairment during early [177Lu]PSMA-617 radioligand therapy: Haematotoxicity or tumour progression?

Safety and efficacy of 177Lutetium-PSMA-617 radioligand therapy shortly after failing 223Radium-dichloride

Safety and efficacy of 177Lutetium-PSMA-617 radioligand therapy shortly after failing 223Radium-dichloride

Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy

Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy

Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy

Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy

Related objects